A Phase 1/ Phase 2 Study of TTHX1114(NM141)

Key Inclusion Criteria: * Fuchs Endothelial Corneal Dystrophy, pseudophakic bullous keratopathy, or endothelial dysfunction/ insufficiency due to surgical intervention diagnosed more than 6 months prior to Study Day 0 * Central endothelial cell count of \< 2000 mm\^2 in at least one eye as determined by the central reading facility Key Exclusion Criteria: * Conditions that would impair examination of the anterior chamber structure * Documented repeated elevated intra ocular pressure (in either eye) * Corneal transplant (in either eye) * Posterior Polymorphous Corneal Dystrophy (PPCD) * History of uveitis or herpetic keratitis * Cataract surgery within the past 3 months * Refractive surgery (in the Study Eye) * Anterior Chamber IOL placement (in the Study Eye) * Active extra-ocular inflammation from any non-infectious or infectious cause within the past 6 months * Expected or planned ocular surgery within the next 3 months * Use of cytotoxic chemotherapy within the last 1 month * Treatment with a rho kinase inhibitor within the last 3 months * Use of cyclosporine ophthalmic emulsion or lifitegrast ophthalmic solution in the last 30 days * Systemic or ophthalmic corticosteroid use in the 30 days prior to Study Day 0 unless approved by the Medical Monitor * History of significant allergy, hypersensitivity, or intolerance to any drug compound, food, or other substance * Unwilling to use birth control